» Articles » PMID: 32925082

Large Animal Models of Huntington's Disease: What We Have Learned and Where We Need to Go Next

Overview
Publisher Sage Publications
Date 2020 Sep 14
PMID 32925082
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Genetically modified rodent models of Huntington's disease (HD) have been especially valuable to our understanding of HD pathology and the mechanisms by which the mutant HTT gene alters physiology. However, due to inherent differences in genetics, neuroanatomy, neurocircuitry and neurophysiology, animal models do not always faithfully or fully recapitulate human disease features or adequately predict a clinical response to treatment. Therefore, conducting translational studies of candidate HD therapeutics only in a single species (i.e. mouse disease models) may not be sufficient. Large animal models of HD have been shown to be valuable to the HD research community and the expectation is that the need for translational studies that span rodent and large animal models will grow. Here, we review the large animal models of HD that have been created to date, with specific commentary on differences between the models, the strengths and disadvantages of each, and how we can advance useful models to study disease pathophysiology, biomarker development and evaluation of promising therapeutics.

Citing Articles

RNA-Targeting CRISPR/CasRx system relieves disease symptoms in Huntington's disease models.

Lin Y, Li C, Chen Y, Gao J, Li J, Huang C Mol Neurodegener. 2025; 20(1):4.

PMID: 39806441 PMC: 11727607. DOI: 10.1186/s13024-024-00794-w.


Neuroinflammatory Proteins in Huntington's Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications.

Li X, Tong H, Xu S, Zhou G, Yang T, Yin S Int J Mol Sci. 2024; 25(21).

PMID: 39519337 PMC: 11546928. DOI: 10.3390/ijms252111787.


Magnetic Resonance Imaging to Detect Structural Brain Changes in Huntington's Disease: A Review of Data from Mouse Models.

Hanrahan J, Locke D, Cahill L J Huntingtons Dis. 2024; 13(3):279-299.

PMID: 39213087 PMC: 11494634. DOI: 10.3233/JHD-240045.


Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs.

Huang H, Wu S, Chowdhury E, Shah D J Pharmacokinet Pharmacodyn. 2023; 51(6):621-638.

PMID: 37947924 DOI: 10.1007/s10928-023-09893-5.


Reduced D /D Receptor Binding and Glucose Metabolism in a Macaque Model of Huntington's Disease.

Weiss A, Bertoglio D, Liguore W, Brandon K, Templon J, Link J Mov Disord. 2022; 38(1):143-147.

PMID: 36544385 PMC: 9948637. DOI: 10.1002/mds.29271.


References
1.
Richter A, Hamann M, Wissel J, Volk H . Dystonia and Paroxysmal Dyskinesias: Under-Recognized Movement Disorders in Domestic Animals? A Comparison with Human Dystonia/Paroxysmal Dyskinesias. Front Vet Sci. 2015; 2:65. PMC: 4672229. DOI: 10.3389/fvets.2015.00065. View

2.
Uchida M, Shimatsu Y, Onoe K, Matsuyama N, Niki R, Ikeda J . Production of transgenic miniature pigs by pronuclear microinjection. Transgenic Res. 2002; 10(6):577-82. DOI: 10.1023/a:1013059917280. View

3.
Kocerha J, Liu Y, Willoughby D, Chidamparam K, Benito J, Nelson K . Longitudinal transcriptomic dysregulation in the peripheral blood of transgenic Huntington's disease monkeys. BMC Neurosci. 2013; 14:88. PMC: 3751855. DOI: 10.1186/1471-2202-14-88. View

4.
Chan A, Jiang J, Chen Y, Li C, Prucha M, Hu Y . Progressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood. PLoS One. 2015; 10(5):e0122335. PMC: 4428630. DOI: 10.1371/journal.pone.0122335. View

5.
Fan Z, Viotti Perisse I, Cotton C, Regouski M, Meng Q, Domb C . A sheep model of cystic fibrosis generated by CRISPR/Cas9 disruption of the CFTR gene. JCI Insight. 2018; 3(19). PMC: 6237476. DOI: 10.1172/jci.insight.123529. View